First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. Dhakal, B., Yong, K., Harrison, S. J., Mateos, M., Moreau, P., van de Donk, N. J., Sidana, S., Popat, R., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J., Li, K., Zudaire, E., Chen, Y., Gilbert, J., Bubuteishvili-Pacaud, L., Patel, N., San-Miguel, J., Einsele, H. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001043181100008